Curve Therapeutics

Curve Therapeutics is a drug discovery company using its proprietary platform to identify first-in-class small molecule therapeutics against targets that have been difficult to address using conventional methods.

The platform screens gene-encoded cyclic peptide libraries inside mammalian cells to identify functionally active hits, which are then converted to non-peptide small molecules for lead optimisation.

The company's pipeline includes inhibitors of HIF-1/HIF-2 and ATIC dimerisation in oncology.

Curve has a $1.7bn global research collaboration with MSD.